Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Checked against the public recordLast updated Jun 17, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Pharmacosmos A/S
- Interventions being studied
- Drug: Trilaciclib; Drug: Saline (0.9% NaCl)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer * Complete recovery from prior anti-tumor surgical procedures * Measurable and evaluable disease through tumor assessment * Willingness to participate and sign informed consent form Exclusion Criteria: * Extensive Stage Small Cell Lung Cancer * Active cardiovascular disease * Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations * Pregnant or nursing women
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pharmacosmos Investigational SiteOakland, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 17, 2026. Always confirm current availability with the study team.